Strategic Performance Drivers – Achieved record organic orders growth of 11.1% and a record backlog of $23.9 billion, driven by healthy end-market demand and successful commercial realignment. – Performance was led by Pharmaceutical Diagnostics (PDx) and Advanced Imaging…
lutions (AIS), which combined for 6.5% growth and 100 basis points of margin expansion. – Patient Care Solutions (PCS) remained challenged due to operational fulfillment issues and supply chain constraints, prompting a comprehensive strategic review of the business. – The ‘D3’ strategy (Devices, Drugs, Digital) is gaining traction, with AI-enabled innovations like True Definition DL and Vivid Pioneer driving higher pricing and improved gross margins. – Management attributed the strong order book to improved field execution and a higher win rate facilitated by the ‘Heartbeat’ operational business system. – Market demand for contrast media remains robust, with current global demand nearly outpacing total market supply, supporting strong PDx volume and pricing. Outlook and Strategic Assumptions – Maintained full-year 2026 guidance, assuming 3%-4% organic sales growth and 10-40 basis points of adjusted EBIT margin expansion. – Expects significant margin improvement in the second half of 2026, driven by price-cost actions and the scaling of higher-margin new product introductions (NPIs). – The strategic review of PCS includes options ranging from continued ownership to a potential sale or other value-enhancing transactions to maximize long-term growth. – Maintained the medium-term target for the radiopharmaceutical business to reach $500 million or more in annual revenue by 2028, supported by the Flyrcado ramp. – Guidance for 2026 assumes a year-over-year decline in China, though management views the expansion of Volume-Based Procurement (VBP) as a manageable, transparent shift
Operational and Structural Dynamics – Recognized $23 million in P&L refunds from IEEPA tariffs in Q2, with a total of $107…